Perspective Therapeutics’ (CATX) Buy Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of Perspective Therapeutics (NYSEAMERICAN:CATX) in a research note published on Wednesday morning,Benzinga reports. The firm currently has a $14.00 price target on the stock.

Several other equities research analysts have also weighed in on the company. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, September 15th. William Blair initiated coverage on Perspective Therapeutics in a research note on Friday, September 18th. They issued an “outperform” rating on the stock. BMO Capital Markets set a $11.00 price target on Perspective Therapeutics and gave the company an “outperform” rating in a research report on Tuesday, August 18th. Bank of America dropped their price objective on Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research note on Friday, August 14th. Finally, Piper Sandler cut their price objective on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $11.50.

Perspective Therapeutics Trading Down 1.8%

Shares of Perspective Therapeutics stock opened at $2.66 on Wednesday. The firm’s 50-day simple moving average is $2.94 and its 200-day simple moving average is $3.40. Perspective Therapeutics has a twelve month low of $1.96 and a twelve month high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.03. The firm had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.09 million. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. On average, equities analysts forecast that Perspective Therapeutics will post -0.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of CATX. Dimensional Fund Advisors LP increased its holdings in Perspective Therapeutics by 391.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 450,097 shares of the company’s stock valued at $1,877,000 after purchasing an additional 358,540 shares in the last quarter. Avidity Partners Management LP boosted its stake in Perspective Therapeutics by 88.4% in the first quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock worth $25,228,000 after purchasing an additional 2,839,266 shares in the last quarter. Seven Fleet Capital Management LP bought a new stake in shares of Perspective Therapeutics during the first quarter worth $1,581,000. Yu Fan bought a new stake in shares of Perspective Therapeutics during the first quarter worth $4,401,000. Finally, Commodore Capital LP acquired a new stake in shares of Perspective Therapeutics in the first quarter valued at $26,424,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc is a clinical-stage radiopharmaceutical biotechnology company developing precision-targeted alpha therapies for cancer. The company’s approach combines tumor-targeting molecules with radioactive isotopes to deliver highly focused radiation to cancer cells while limiting exposure to surrounding healthy tissue.

Perspective’s proprietary VMT platform is designed to support both diagnostic imaging and therapeutic applications. Its lead programs include VMT-α-NET, an investigational therapy targeting somatostatin receptor 2 for patients with neuroendocrine tumors, and VMT01, an investigational program targeting melanocortin 1 receptor-expressing cancers, including certain metastatic melanomas.